{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreievpfmnvlkn3t75pugcuvn7uau7tsow6st3kjzbrl7cw26nmwqq54",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mi53t54ggms2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreidfhycln6mwfj6td7wwkxiungh7e2bpwjfeexs4mtt3dok5ky5enm"
    },
    "mimeType": "image/jpeg",
    "size": 726877
  },
  "path": "/news/2026-03-fda-gene-therapy-severe-leukocyte.html",
  "publishedAt": "2026-03-28T11:30:02.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "Dr. Donald Kohn has been developing gene therapies for rare pediatric immune disorders for over 30 years. This week, his role in a clinical trial has culminated in the first-ever U.S. Food and Drug Administration–approved therapy for severe leukocyte adhesion deficiency-I—a genetic condition characterized by recurrent infections and, often, early death.",
  "title": "FDA approves gene therapy for severe leukocyte adhesion deficiency-I, a rare immune disorder"
}